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MaOBJECTIVES The purpose of this study was to examine the prognostic signiﬁcance of left ventricular (LV) mass for
cardiovascular disease (CVD) events in older adults with and without metabolic syndrome (MetS) and diabetes mellitus (DM).
BACKGROUND MetS and DM are associated with increased CVD risk, but it is unclear in these groups whether
subclinical CVD as shown by increased LV mass improves risk prediction compared to standard risk factors in older
individuals.
METHODS We studied 3,724 adults (mean 72.4  5.4 years of age, 61.0% female, 4.4% African-American) from the
Cardiovascular Health Study who had MetS but not DM or had DM alone or had neither condition. Cox regression was
used to examine the association of LV mass, (alone and indexed by height and body surface area [BSA]) as determined by
echocardiography, with CVD events, including coronary heart disease (CHD), stroke, heart failure (HF), and CVD death, as
well as total mortality. We also assessed the added prediction, discriminative value, and net reclassiﬁcation improvement
(NRI) for clinical utility of LV mass compared to standard risk factors.
RESULTS Over a mean follow-up of 14.2  6.3 years, 2,180 subjects experienced CVD events, including 986 CVD
deaths. After adjustment for age, sex and standard risk factors, LV mass was positively associated with CVD events in
those with MetS (hazard ratio [HR]: 1.4, p < 0.001) and without MetS (HR: 1.4, p < 0.001), but not DM (HR: 1.0, p ¼
0.62), with similar ﬁndings for LV mass indexed for height or BSA. Adding LV mass to standard risk factors moderately
improved the prediction accuracy in the overall sample and MetS group from changes in C-statistics (p < 0.05).
Categorical-free net reclassiﬁcation improvement increased signiﬁcantly by 17% to 19% in those with MetS. Findings
were comparable for CHD, CVD mortality, and total mortality.
CONCLUSIONS LV mass is associated with increased CVD risk and provides modest added prediction and clinical utility
compared to standard risk factors in older persons with and without MetS but not with DM. (J Am Coll Cardiol Img
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ABBR EV I A T I ON S
AND ACRONYMS
BMI = body mass index
BSA = body surface area
CHD = coronary heart disease
CVD = cardiovascular disease
DM = diabetes mellitus
LDL-C = low-density
lipoprotein cholesterol
LV = left ventricular
MetS = metabolic syndrome
NRI = net reclassiﬁcation i
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1008O lder persons with metabolic syn-drome (MetS) and diabetes melli-tus (DM) are more likely to have
subclinical atherosclerosis and are at greater
risk of cardiovascular disease (CVD) events
(1–3) and mortality (4). Previous studies
have identiﬁed left ventricular (LV) mass
independently predicts CVD events (5–7).
Although the association of MetS (5) and the
number of MetS risk factors (7) with LV
mass has been demonstrated, and DM
adversely impacts hypertrophic remodeling
through increased LV mass and larger cavitydimensions (8), there are limited data examining the
value of LV mass for predicting CVD events in persons
with MetS or DM. Although a smaller previous study
compared the prognosis of increased LV mass in dia-
betic and nondiabetic hypertensive individuals (9),
to our knowledge, no population-based study has
compared the prognostic signiﬁcance of LV mass in
persons with and without MetS and DM. Although
ndexSEE PAGE 1016DM is a well-known risk factor for coronary heart dis-
ease (CHD), it has been shown by some studies to
confer a lower risk of subsequent cardiac complica-
tions than CHD (10). There is a need to better identify
what other screening methods for subclinical CVD can
further improve risk prediction in persons with MetS
and DM (11). For instance, it is known such persons
demonstrate a greater extent of myocardial ischemia
(12) and coronary calcium (13,14), with the latter
providing prognostic value for CVD events (15).
Whether subclinical CVD as shown by higher LV
mass provides signiﬁcant incremental prognostic
value in predicting CVD events compared to standard
risk factors under these conditions is unclear, espe-
cially in those with MetS and DM and in older persons
who have a longer exposure to these conditions. Such
information would be useful to judge the utility of LV
mass assessment in these groups.
This study examined whether readily available
echocardiographic measurements of LV mass added
to standard CVD risk factors in the prediction of CVD
events in older persons with and without MetS or DM.
Our analysis addressed the question of whether there
is a role for these readily available measurements in
risk stratiﬁcation for these populations.
METHODS
STUDY SAMPLE AND RECRUITMENT. Our analyses
included 3,724 adults 65 to 95 years of age from the
Cardiovascular Health Study (CHS), a prospective U.S.National Institutes of Health-sponsored study of older
adults, which studied risk factors and subclinical
measurements of CVD and their outcomes. Initial
enrollment from 1989 to 1990 recruited 5,201 partici-
pants, whereas a second cohort of 687 African-
American participants was recruited from 1992 to
1993. Speciﬁcally, of the initial cohort of 5,201 sub-
jects, the current analysis included CHS participants
who had baseline measurements of LV mass from
2-dimensionally directed M-mode echocardiography
as well as information for incidence of CVD events;
patients with prior CVD events were excluded. Par-
ticipants were initially recruited from Heath Care
Financing Administration Medicare eligibility lists
and other household members from 4 U.S. geo-
graphic regions: Forsyth County, North Carolina;
Sacramento County, California; Washington County,
Maryland; and Pittsburgh, Pennsylvania. Participant
consent was obtained during baseline examination.
Baseline examination data consisted of medical his-
tory, physical examination, and fasting blood ana-
lyses. The methodology and design of CHS have been
previously reported (15). Up to 22 years of follow-up
data were available through June 30, 2004, with vi-
tal status known for all 3,724 subjects included in the
study, with complete risk factor data (no persons lost
to follow-up). This project was exempt from Institu-
tional Review Board review due to the use of de-
identiﬁed data.
MEASUREMENTS. Risk factors were measured by
standardized methodology, as previously described,
and included systolic and diastolic blood pressure
(BP), low-density lipoprotein cholesterol (LDL-C) and
high-density lipoprotein-cholesterol (HDL-C), tri-
glycerides, glucose, waist circumference, and body
mass index (BMI) (15). Subjects were classiﬁed as
having MetS without DM (according to American
Heart Association/National Heart, Lung, and Blood
Institute [AHA/NHLBI] criteria], or DM, or neither
condition. MetS (n ¼ 1,178) without DM was deﬁned,
according to the AHA/NHLBI deﬁnition (16), as having
any 3 of the following 5 criteria: elevated BP ($130
systolic or $85 mm Hg) or treatment for hyperten-
sion; low HDL-C (<40 mg/dl in males or <50 mg/dl
in females); elevated triglycerides ($150 mg/dl);
increased waist circumference (>88 cm [35 inches] in
females or >102 cm [40 inches] in males); or impaired
fasting glucose (100 to 125 mg/dl). DM (n ¼ 485 sub-
jects) was deﬁned as having a fasting glucose con-
centration of $6.9 mmol/l (126 mg/dl), taking oral
hypoglycemic medication, or self-reported use of
insulin. Subjects with neither condition (n ¼ 2,061)
were also included in our analyses.
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1009The protocol for performing and reading
transthoracic echocardiograms has been previously
described (17). Brieﬂy, a baseline echocardiogram was
recorded onto super-VHS tape by using a standard-
ized protocol, with measurements made at the
Echocardiography Reading Center at University of
California, Irvine, from 1989 to 1990, and at George-
town University from 1992 to 1993 from digitized
images, using an off-line image analysis system
equipped with customized computer algorithms.
Quality control measurements included standardized
training of sonographers and readers, periodic
observation of a sonographer by a trained echocardi-
ographer, and blind duplicate readings to establish
inter-reader and intrareader measurement vari-
ability. This study focused on 2-dimensionally
directed M-mode measurements of LV mass, which
were calculated as described by Devereux et al. (18),
where LV mass (g) ¼ 0.80  1.04 [(VSTd þ LVIDd þ
PWTd)3  (LVIDd)3] þ 0.6 cm, where VSTd ¼ ven-
tricular septal thickness in diastole; LVIDd ¼ LV in-
ternal dimension in diastole; and PWTd ¼ posterior
wall thickness in diastole. We also present our data
according to LV mass indexed to height (cm1.7), given
that this variable has been recently proposed to
represent more accurate scaling (19) than olderTABLE 1 Baseline Characteristics
Overall
(n ¼ 3,724)
Neither
(n ¼ 2,061)
Age, yrs 72.4  5.4 72.5  5.6
Males 1453 (39.0) 828 (40.2)
African American 165 (4.4) 84 (4.1)
Systolic BP, mm Hg 135.5  21.0 131.8  21.1
Diastolic BP, mm Hg 70.7  11.1 69.7  11.0
Triglycerides, mg/dl 139.3  73.0 110.0  40.7
Total cholesterol, mg/dl 212.7  39.0 211.3  36.4
LDL-C, mg/dl 130.1  35.7 128.3  33.8
HDL-C, mg/dl 55.4  15.8 61.1  15.7
Waist circumference, cm 93.4  12.9 88.2  11.5
Glucose, mg/dl 108.4  31.5 96.5  8.3
Body mass index, kg/m2 26.4  4.5 24.6  3.64
Hypertension medication 1,372 (36.8) 511 (24.8)
Lipid-lowering medication 156 (4.2) 70 (3.4)
Obesity 663 (17.8) 129 (6.3)
Smoking status
Nonsmoker 1,784 (47.9) 966 (46.9)
Former smoker 1,504 (40.4) 845 (41.0)
Current smoker 436 (11.7) 250 (6.7)
LV mass, g 149.3  29.9 142.4  28.4
Indexed LV mass, g/m1.7 63.8  10.6 60.8  9.8
Indexed LV mass, g/m2 84.5  11.2 82.8  11.1
Values are mean  SD or n (%).
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholescaling (such as by a power of 2.7) as well as by body
surface area (BSA).
CVD and CHD events were adjudicated by the CHS
endpoints committee of physician investigators.
Incident CVD was deﬁned as CHD, stroke, heart fail-
ure (HF), or claudication, with CVD deaths due to
either of these incident conditions. CHD events
included incident nonfatal myocardial infarction,
angina requiring hospitalization, coronary artery an-
gioplasty, coronary bypass surgery, or death caused
by “atherosclerotic CHD.” CHS criteria for angina
required a report of symptoms such as chest pain,
chest tightness, or shortness of breath; the diagnosis
of angina from a physician; and being under medical
treatment for angina (including nitroglycerin, beta
blocker, or calcium channel blocker). Total CVD and
CHD events, CVD mortality, and total mortality were
deﬁned as occurring after the baseline echocardio-
graphic assessment of LV mass. The ﬁrst occurrence
of a qualifying event was used as the individual’s
“event,” so recurrent events were not included in the
analysis. Follow-up time was deﬁned from the base-
line LV mass echocardiographic assessment to the
date of ﬁrst occurrence of a CVD event (or CHD, CVD
death, or total mortality for analyses speciﬁc to those
endpoints).Metabolic Syndrome
(n ¼ 1,178)
Diabetes
(n ¼ 485) p Value
72.2  5.1 72.6  5.5 0.16
400 (34.0) 225 (46.4) <0.0001
36 (3.1) 45 (9.3) <0.0001
139.8  19.7 140.8  20.9 <0.0001
72.1  10.7 71.9  11.8 <0.0001
175.8  76.3 175.1  107.8 <0.0001
217.6  40.8 206.7  43.8 <0.0001
135.3  37.0 125.6  39.1 <0.0001
48.3  12.8 48.1  13.1 <0.0001
99.7  11.6 99.5  12.1 <0.0001
105.0  8.96 166.9  55.3 <0.0001
28.7  4.49 28.3  4.73 <0.0001
594 (50.4) 267 (55.1) <0.0001
63 (5.3) 23 (4.7) 0.02
372 (31.6) 162 (33.4) <0.0001
0.53
588 (49.9) 230 (47.4)
458 (38.9) 201 (41.4)
132 (3.5) 54 (11.1)
155.7  28.3 163.6  31.6 <0.0001
66.9  9.8 69.1  11.4 <0.0001
85.6  10.2 89.0  12.4 <0.0001
sterol; LV ¼ left ventricle/ventricular.
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1010STATISTICAL ANALYSIS. Descriptive statistics of pro-
portions for categorical variables and mean  SD
for continuous variables are presented by disease
group and compared by using chi-square test of pro-
portions or analysis of variance among groups,
respectively. Cox proportional hazards regression
analysis was used to examine the association of LV
mass with time to the primary outcome of a ﬁrst CVD
event and with time to the secondary endpoints of
CHD, CVD mortality, and total mortality, providing
hazard ratios (HRs) and 95% conﬁdence intervals (CIs).
These analyses were adjusted for age, sex, ethnicity,
and standard risk factors (systolic BP, diastolic
BP, hypertensive medications, HDL-C, LDL-C, total
cholesterol, triglycerides, lipid medications, BMI,
and fasting glucose). LV mass was stratiﬁed according
to sex-speciﬁc quartiles in grams and was also exam-
ined continuously according to SD of LV mass
indexed by height (g/m1.7), SD of LV mass indexed by
BSA (g/m2), and SD of LV mass of 30 g. The area under
the receiving operator characteristic curve (AUC) was
used to examine the incremental value of LV mass
above standard risk factors for the prediction
of CVD events. We constructed logistic regression
models with and without LV mass measurements to
compare AUC differences. In addition, to examine theFIGURE 1 Total Cardiovascular Disease Event Rates
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Total cardiovascular disease event rates (per 1,000 person years) by LV
vascular event rate is observed across increasing LV mass quartiles for t
DM ¼ diabetes mellitus; LV ¼ left ventricular mass; MetS ¼ metabolic sadded clinical utility of echocardiographic LV mass
compared to standard risk factors, the category-free
NRI was calculated as: [(number of events reclassiﬁed
with higher risk  number of events reclassiﬁed
with lower risk)/number of events] þ [(number of
nonevents reclassiﬁed as lower risk  number of non-
events reclassiﬁed as higher risk)/number of non-
events]. SAS statistical software version 9.4 (SAS
Institute, Cary, North Carolina) (20) was used for
analysis. A p value of <0.05 (and a p value of <0.1
for interaction test) was considered statistically
signiﬁcant.
RESULTS
SUBJECT CHARACTERISTICS. The age of our 3,274
participants was 72.4  5.4 years, with 61% females
and 4.4% African Americans (Table 1). As expected,
participants with MetS or DM had signiﬁcantly higher
mean BPs, lipid measurements, serum glucose, BMI,
and LV mass than persons with neither disease. LV
mass values for those with MetS, DM, or neither were
155.7  28.3 g, 163.5  31.6 g, and 142.4  28.4 g,
respectively (p < 0.0001). Mean LV mass values
indexed to height (LV mass [g/m1.7]) for those
with MetS, DM, or neither were 66.9  9.8 g/m,3rd
Quartile
4th
Quartile
ach Disease Group
4.3
44.8
55.9
73.4
60.4
80.8
111.0
DMMetS
mass quartile within the disease group. A higher unadjusted cardio-
hose with neither MetS nor DM, MetS without DM, or those with DM.
yndrome.
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101169.1  11.4 g/m, and 60.8  10.6 g/m, respectively
(p < 0.0001). Mean LV mass values indexed to BSA
(LV mass in g/BSA [m2]) for those with MetS, DM,
or neither were 85.6  10.2 g/m2, 89.0  12.4 g/m2,
and 82.8  11.1 g/m2, respectively (p < 0.0001).
CARDIOVASCULAR DISEASE EVENTS. Over a mean
follow-up of 14.2  6.3 years, 2,180 participants
experienced at least 1 CVD event. Unadjusted rates of
total CVD events per 1,000 person years were highest
in those with DM. A stepwise increase of unadjusted
rates of total CVD events per 1,000 person years was
observed across quartiles of LV mass for those with
MetS and DM and those with neither condition
(Figure 1).
RELATIONSHIP BETWEEN LV MASS AND OUTCOMES.
Findings from adjusted Cox proportional hazards
regression are shown in Table 2 for primary (total
CVD) and secondary outcomes (total CHD, CVD mor-
tality, and all-cause mortality). In participants with
neither MetS nor DM and persons with MetS alone,
higher LV mass and indexed LV mass were risk
factors for total CVD, total CHD, CVD mortality, and
all-cause mortality. These associations were not
observed in persons with DM. Interaction test resultsTABLE 2 Standardized Hazard Ratios of Variables by Disease Group*
n (%)
HR per S
(9
Total CVD
Neither MetS/DM (n ¼ 2,061) 1,098 (53.3) 1.37 (0
MetS (without DM) (n ¼ 1,178) 746 (63.3) 1.38 (1
DM (n ¼ 485) 336 (69.3) 0.99 (0
Overall (n ¼ 3,724) 2,180 (58.5) 1.28 (1
Total CHD
Neither MetS/DM (n ¼ 2,061) 672 (32.6) 1.37 (1
MetS (without DM) (n ¼ 1,178) 477 (40.5) 1.29 (1
DM (n ¼ 485) 219 (45.2) 0.93 (0
Overall (n ¼ 3,724) 1,368 (36.7) 1.22 (1
CVD Mortality
Neither MetS/DM (n ¼ 2,061) 493 (23.9) 1.60 (1
MetS (without DM) (n ¼ 1,178) 311 (26.4) 1.41 (1
DM (n ¼ 485) 182 (37.5) 1.00 (0
Overall (n ¼ 3,724) 986 (26.5) 1.39 (1
All-cause mortality
Neither MetS/DM (n ¼ 2,061) 1,565 (75.9) 1.24 (1
MetS (without DM) (n ¼ 1,178) 919 (78.0) 1.22 (1
DM (n ¼ 485) 438 (90.3) 1.07 (0
Overall (n ¼ 3,724) 2,922 (78.5) 1.22 (1
Values are adjusted for age, sex, ethnicity, systolic BP, diastolic BP, hypertensive medicat
mass ¼ 30 g; SD of indexed LV mass/height ¼ 10.6 g/m; SD of LV mass/BSA ¼ 11.2 g/m
among CVD/CHD events, CVD mortality, and all-cause mortality by disease group. *p <
BMI ¼ body mass index; BP ¼ blood pressure; BSA ¼ body surface area; CHD ¼
DM ¼ diabetes mellitus; HDL ¼ high-density lipoprotein; HR ¼ hazard ratio; LDL ¼ lowfor disease groups and LV mass were signiﬁcant for
total CHD (p ¼ 0.049), CVD death (p ¼ 0.057), and
total mortality (p ¼ 0.060); for disease groups and LV
mass indexes, results were only signiﬁcant for CVD
death in relation to LV mass/height1.7 (p ¼ 0.064) and
for LV mass/BSA (p ¼ 0.029). Similar ﬁndings were
noted when subjects were stratiﬁed by sex. Both men
and women with neither disease or with MetS alone
had a higher risk of total CVD events per SD of in-
crease in LV mass; men and women with DM did
not (Table 3).
Although unadjusted HR values for CVD events in
relation to LV mass (per SD) were signiﬁcant
(p < 0.01) in all 3 disease groups, they were weaker in
those with DM (HR: 1.16) than in those with MetS (HR:
1.27) or neither condition (HR: 1.25), and in those with
DM were further attenuated to being nonsigniﬁcant
after adjustment for sex (higher LV mass and event
rates in men with DM), age, systolic BP, and choles-
terol in particular. In addition, the relationship of LV
mass with CVD events did not differ between men
and women (interaction test results were not signiﬁ-
cantly different). Because <5% of our subjects (n ¼
165) were African American, the sample size was
insufﬁcient to show relationships with CVD eventsD LV Mass (g)
5% CI)
HR per SD LV
Mass/Height (g/m1.7)
(95% CI)
HR per SD LV
Mass/BSA (g/m2)
(95% CI)
.123–1.53)† 1.29 (1.18–1.42)† 1.23 (1.14–1.32)†
.22–1.57)† 1.29 (1.16–1.45)† 1.25 (1.13–1.67)†
.86–1.13) 1.06 (0.94–1.19) 1.04 (0.94–1.15)
.20–1.37)† 1.25 (1.17–1.32)† 1.20 (1.14–1.26)†
.20–1.56)† 1.35 (1.21–1.51)† 1.26 (1.16–1.38)†
.11–1.51)‡ 1.22 (1.06–1.40)‡ 1.19 (1.06–1.34)‡
.77–1.12) 1.07 (0.92–1.24) 1.05 (0.93–1.19)
.13–1.32)† 1.24 (1.15–1.33)† 1.19 (1.13–1.27)†
.39–1.86)† 1.53 (1.35–1.73)† 1.39 (1.26–1.53)†
.15–1.73)§ 1.44 (1.22–1.70)† 1.37 (1.19–1.57)†
.82–1.22) 1.09 (0.91–1.29) 1.07 (0.93–1.23)
.27–1.52)† 1.41 (1.29–1.53)† 1.33 (1.24–1.42)†
.13–1.36)† 1.22 (1.12–1.32)† 1.17 (1.10–1.24)†
.08–1.39)‡ 1.18 (1.06–1.32)‡ 1.16 (1.06–1.26)‡
.94–1.21) 1.09 (0.91–1.22) 1.08 (0.98–1.19)
.15–1.30)† 1.20 (1.13–1.26)† 1.16 (1.11–1.21)†
ions, HDL, LDL, total cholesterol, lipid medications, BMI, and fasting glucose. SD of LV
2. Data are standardized hazard ratios of LV mass/LV mass indexes with relationships
0.05. †p < 0.0001. ‡p < 0.01. §p < 0.001.
congenital heart disease; CI ¼ conﬁdence interval; CVD ¼ cardiovascular disease;
-density lipoprotein; MetS ¼ metabolic syndrome.
TABLE 3 Standardized Hazard Ratios of Total CVD Events for LV Mass/LV Mass Indexes by Sex
n (%)
HR per SD LV Mass, g
(95% CI)
HR per SD LV
Mass, g/Height, m1.7
(95% CI)
HR per SD LV
Mass, g/BSA, m2
(95% CI)
Neither MetS nor DM (N ¼ 2,061) Men (n ¼ 828) 474 (57.2) 1.37 (1.20–1.56)* 1.28 (1.14–1.45)* 1.22 (1.11–1.34)*
Women (n ¼ 1,233) 624 (50.6) 1.39 (1.15–1.68)† 1.31 (1.13–1.53)* 1.23 (1.10–1.39)*
MetS without DM (N ¼ 1,178) Men (n ¼ 400) 263 (65.8) 1.37 (1.14–1.65)† 1.29 (1.09–1.53)‡ 1.24 (1.08–1.43)‡
Women (n ¼ 778) 483 (62.1) 1.36 (1.13–1.63)‡ 1.29 (1.11–1.51)‡ 1.25 (1.10–1.43)†
DM (N ¼ 485) Men (n ¼ 225) 166 (73.8) 1.00 (0.85–1.17) 1.08 (0.93–1.26) 1.07 (0.94–1.22)
Women (n ¼ 260) 170 (65.4) 0.99 (0.74–1.34) 1.00 (0.80–1.24) 0.99 (0.83–1.18)
Overall (N ¼ 3,724) Men (n ¼ 1,453) 903 (62.1) 1.27 (1.17–1.37)* 1.25 (1.16–1.36)* 1.20 (1.13–1.28)*
Women (n ¼ 2,271) 1,277 (56.2) 1.31 (1.17–1.47)* 1.24 (1.13–1.36)* 1.19 (1.11–1.29)*
SD of LV mass ¼ 30 g; SD of indexed LV mass/height ¼ 10.6 g/m; SD of LV mass/BSA ¼ 11.2 g/m2. Risk factors include age, sex, ethnicity, systolic BP, diastolic BP, hypertensive
medications, HDL, LDL, total cholesterol, triglycerides, lipid medications, BMI, and fasting glucose. *p < 0.0001. †p < 0.001. ‡p < 0.01.
Abbreviations as in Table 2.
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1012in those with MetS or DM; however, in those with
neither condition, risks of CVD events (per SD of LV
mass) appeared to be greater in African Americans
(HR: 2.42 [95% CI: 1.26 to 4.64], p < 0.01) than in
whites (HR: 1.36 [95% CI: 1.22 to 1.51], p < 0.001) with
similar ﬁndings for indexed LV mass measurements
(results not shown).
Adjusted Cox proportional hazard models for out-
comes were also examined by quartiles of LV mass.
Participants with neither MetS nor DM and those with
MetS alone who were in the highest quartile of LVFIGURE 2 Adjusted Hazard Ratios for Total Cardiovascular Disease
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A higher adjusted hazard ratio for cardiovascular events is observed acros
for those with MetS without DM, but not in those with DM. *p < 0.01, †p
ventricular mass; MetS ¼ metabolic syndrome.mass had signiﬁcantly increased risks for total
CVD (HR: 1.9 [p < 0.0001] and 2.0 [p < 0.0001],
respectively) compared to those in the ﬁrst
quartile (Figure 2). Similarly, the highest quartile
(versus lowest quartile) of LV mass independently
predicted secondary endpoints of total CHD (HR: 2.0,
p < 0.0001), CVD death (HR: 2.4, p < 0.0001), and all-
cause mortality (HR: 1.5, p < 0.01) in those with
neither condition. Hazard ratios were increased for
total CHD (HR: 1.6, p ¼ 0.03) and CVD death (HR: 1.7,
p ¼ 0.04) but not for all-cause mortality (HR: 1.3,Events by Quartiles of LV Mass Within the Disease Group
e 3rd Quartile 4th Quartile
DMetS
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1.96†
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s increasing LV mass quartiles for those with neither MetS nor DM and
< 0.05 compared to ﬁrst quartile. DM ¼ diabetes mellitus; LV ¼ left
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 9 , 2 0 1 5 Hoang et al.
S E P T E M B E R 2 0 1 5 : 1 0 0 7 – 1 5 LV Mass in Metabolic Syndrome and Diabetes
1013p ¼ 0.13) in those with MetS in the highest versus
lowest quartile of LV mass. In contrast, there was no
signiﬁcant increased risk of both primary and sec-
ondary endpoints across quartiles of LV mass in those
with DM.
The AUC did not show signiﬁcant incremental
predictive value for total incident CVD events be-
tween the base model and the other 3 models for the
prediction of CVD events with LV mass, LV mass/
height1.7 or LV mass/BSA across all 3 disease groups,
except modestly (p < 0.05) for LV mass/height1.7 and
LV mass/BSA in those with MetS (Table 4). There was
also a signiﬁcant (p < 0.05) improvement in c-statistic
in the overall sample comparing models, with LV
mass added to those with risk factors alone, although
the absolute degree of improvement was minimal
(both were 0.63 to the second decimal). We addi-
tionally examined the AUC improvement for CVD
mortality and total mortality. Results showed that
among subjects with neither disease, AUC increased
from 0.64 to 0.66 (p < 0.05) for all 3 LV mass scores.
AUCs for total mortality ranged from 0.70 to 0.74
after including LV mass measurements in the model,
but the improvement was not signiﬁcant (data not
shown).
Analysis results from NRI showed modest added
clinical utility for prediction of CVD events and
ranged from 4% to 7% in the nondisease group and
17% to 19% in the MetS group but was signiﬁcant only
in the MetS group (p < 0.01), comparing the base
model and models with 3 forms of LV mass mea-
surements; however, in those with DM, NRI was not
signiﬁcant (Table 5). In the overall sample, there was
a signiﬁcant NRI from 9% to 10% (p < 0.01). NRI
values for CVD mortality were 9% to 15% in the 3
disease groups (p < 0.05 in MetS and no disease group
for LV mass/height1.7 and LV mass/BSA). NRI values
for total mortality were greatest in those patients
with MetS (10%; p value was not signiﬁcant), and
was <5% in the other 2 groups (p ¼ nonsigniﬁcant;
data not shown).TABLE 4 AUC for Models With LV Mass and Risk Factors Versus Mod
Base Model
(Risk Factors)
Base Model vs
(LV Mass þ Risk
Neither MetS nor DM (n ¼ 2,061) 0.62 0.62
MetS (without DM) (n ¼ 1,178) 0.61 0.63
DM (n ¼ 485) 0.65 0.65
Overall (n ¼ 3,724) 0.63 0.63*
Risk factors include age, sex, ethnicity, systolic BP, diastolic BP, hypertensive medication
AUC ¼ area under the receiver operating characteristic curve; other abbreviations as iDISCUSSION
Our study found that increased LV mass (highest
quartile) was associated with increases in risk for to-
tal CVD events, total CHD events, and CVD and total
mortality in those with and without MetS but not in
those with DM. Our paper is the ﬁrst to report added
discriminative and clinical utility for echocardio-
graphic LV mass over standard CVD risk factors using
ROC and NRI techniques.
Our report corroborates earlier ﬁndings from
shorter-term follow-up regarding the overall rela-
tionship of echocardiographic predictors (including
LV mass) to CVD events in the entire CHS cohort by
Gardin et al. (5). In addition, Kuller et al. (21) previ-
ously reported among persons with DM that the
general presence of subclinical CVD (from the pres-
ence of a low ankle-brachial index, increased carotid
intimal medial thickness or stenosis, major ECG ab-
normalities, or angina) was associated with a 2-fold
greater risk of incident CHD. More recently, in the
longitudinal MESA (Multiethnic Study of Atheroscle-
rosis), LV mass measured by cardiac magnetic reso-
nance imaging was shown to improve the c-statistic
over traditional risk factors for the prediction of
incident HF (22), although this relationship was not
examined in those with MetS and DM.
DM is noted to have an adverse effect on hyper-
trophic remodeling through promotion of increases in
LV mass and dimensions (7). The Framingham Heart
study identiﬁed an association among DM and
increased LV wall thickness and mass that was inde-
pendent of traditional risk factors in women but not
in men (23). LV hypertrophy is common in those with
DM, but previous screening modalities such as ECG
and N-terminal pro–B-type natriuretic peptide have
been noted to be inadequate for detecting LV hyper-
trophy (24). Our data also suggest echocardiographic
LV mass has limited utility to stratify risk in persons
with DM, at least in older adults, which comprised our
cohort. Although increased LV mass is a well-knownels With Risk Factors Alone for Prediction of Total CVD Events
. Model
Factors)
Base Model vs. Model
(LV Mass/Height1.7 þ Risk Factors)
Base Model vs. Model
(LV Mass/BSA þ Risk Factors)
0.62 0.62
0.63* 0.63*
0.65 0.65
0.63* 0.63*
s, HDL, LDL, total cholesterol, triglycerides, lipid medications, BMI, and fasting glucose. *p < 0.05.
n Table 2.
TABLE 5 Category-Free NRI for Models with LV Mass and Risk Factors Versus Models with Risk Factors Alone for Prediction of CVD Events
Base model vs. Model
(LV Mass þ Risk Factors)
Base model vs. Model
(LV Mass/Height1.7 þ Risk Factors)
Base model vs. Model
(LV Mass/BSA þ Risk Factors)
Neither MetS nor DM (n ¼ 2,061) 0.04 0.07 0.07
MetS without DM (n ¼ 1,178) 0.17* 0.19* 0.19*
DM (n ¼ 485) 0.03 0.07 0.06
Overall (n ¼ 3,724) 0.10* 0.09* 0.09*
Risk factors include age, sex, ethnicity, systolic BP, diastolic BP, hypertensive medications, HDL, LDL, total cholesterol, triglycerides, lipid medications, BMI, and fasting glucose.
*p < 0.01.
NRI ¼ net reclassiﬁcation improvement; other abbreviations as in Table 2.
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1014marker of end-organ hypertensive damage, a possible
explanation for our lack of a relationship in those
with DM may be their high baseline risk, supported
by the common notion that DM is a coronary risk
equivalent (25) (which would be the case especially in
our older cohort), and hypertension or other highly
prevalent risk factors in older persons with DM may
have obscured our relationships with LV mass in such
persons. Of note, we observe that even though the
unadjusted relation of LV mass with CVD events is
signiﬁcant in those with DM, it is of lower magnitude
than those with MetS and those with neither condi-
tion and is attenuated to being nonsigniﬁcant after
adjustment for age, sex (in particular), systolic BP,
and cholesterol, whereas the LV mass relationship
with CVD events remains signiﬁcant after adjustment
for these and other risk factors in those without DM.
Alternatively, if smaller LV mass is protective, the
prognostic value of LV mass in diabetics may be lost
because of their higher baseline LV mass, particularly
in a cohort of older subjects who have had years of
exposure to DM and more advanced subclinical CVD.
Other measurements that more directly reﬂect
atherosclerosis burden may be more important for
further risk stratiﬁcation of the patient with DM, such
as coronary calcium, which has been shown to add
prognostic value in such patients (13,14). MetS, how-
ever, is a more heterogeneous condition associated
with a wide variation in CVD risk (26), with many
persons at intermediate risk, where further evalua-
tion such as by echocardiographic LV mass may be
helpful for risk stratiﬁcation; our data support this by
showing a modest added value for echocardiographic
LV mass in risk prediction in such persons and in
those without MetS.
STUDY LIMITATIONS. Limitations of our study
include the fact that the unidimensional nature of
our M-mode measurements does not take into ac-
count changes in eccentricity based on long-axis and
short-axis LV measurements; thus, future studies
involving 2- or 3-dimensional echocardiographicrecordings should investigate whether LV mass is
erroneously estimated by M-mode echocardiography
in conditions such as obesity, MetS, and DM, in which
the ventricle may be more spherically shaped. In
fact, Bluemke et al. (27) showed that stroke and CHD
events were better predicted by abnormal LV ge-
ometry (e.g., increased LV mass-to-volume ratio),
whereas HF events were driven primarily by
increased LV mass alone. Our study did not have
measurements of LV geometry or systolic or diastolic
function, which are known to be affected in DM.
However, other studies have shown that LV mass was
the single 2-dimensional echocardiographic mea-
surement consistently associated with total and in-
dividual CVD endpoints (28). Substantially higher
overall CVD event rates in the diabetic group, which
were not further increased by higher LV mass levels,
contrast with those without DM, where increased
LV mass added more to CVD event prediction. Addi-
tionally, most of our cohort was of Caucasian
descent, consequently, our ﬁndings may not be
generalizable to other racial/ethnic groups and to
younger populations.
CONCLUSIONS
Our study shows that in older persons with MetS and
in those without but not in those with DM, echocar-
diographic LV mass is positively associated with in-
creases in total CVD risk, including CHD, HF, and
stroke, and adds modest clinical utility for CVD pre-
diction compared with standard risk factors. Thus,
measurement of LV mass, although possibly useful to
stratify risk in older persons without DM, may be of
limited clinical utility in those with DM, who are
already at signiﬁcant CVD risk.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Evalua-
tion of left ventricular mass using 2-dimensionally guided
M-mode echocardiography is known to provide risk
stratiﬁcation for future cardiovascular events beyond in-
formation provided by standard risk factors. This study
conﬁrms these ﬁndings in older adults generally and in
those without diabetes, including those with and without
metabolic syndrome. The weaker role of left ventricular
mass for improving risk prediction in those with diabetes
may be due to the important effect of other risk factors.
TRANSLATIONAL OUTLOOK: Older persons and
especially those with diabetes have signiﬁcant but often
varied risks for developing cardiovascular events. Future
studies might examine the roles of other structural and
functional characteristics, especially measured by newer
technologies such as cardiac magnetic resonance for
further reﬁning cardiovascular risk prediction in such
patients.
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